Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL304826 | 0.86 | ALDH1A1 (0.33) | ALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL4920279 | 0.85 | ALDH1A1 (0.50) | ALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL4618360 | 0.83 | — | — | |
| SCHEMBL9210989 | 0.81 | LMNA (0.46) | ALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL7758121 | 0.80 | ALDH1A1 (0.39) | ALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL28198758 | 0.80 | — | — | |
| SCHEMBL304763 | 0.80 | ALDH1A1 (0.50) | ALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL15169922 | 0.77 | ALDH1A1 (0.31) | ALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL3891259 | 0.76 | — | — | |
| SCHEMBL28100023 | 0.75 | TSHR (0.38) | ALDH1A1TDP1CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202322-B2 | Resorcinol derivatives | SUTTER BAY HOSPITALS (US) | 2019-02-12 | — | — | US | claimed |
| US-20180170846-A1 | RESORCINOL DERIVATIVES | SUTTER WEST BAY HOSPITALS | 2018-06-21 | — | — | US | claimed |
| EP-2433937-B1 | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | PURDUE PHARMA LP (US) | 2016-06-29 | — | — | EP | claimed |
| EP-2086958-B1 | SUBSTITUTED-QUINOXALINE-TYPE-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2015-01-14 | — | — | EP | claimed |
| US-20130209483-A1 | CANNABIDINOID DERIVATIVES | SUTTER WEST BAY HOSPITALS (US) | 2013-08-15 | — | — | US | claimed |
| WO-2023067251-A1 | COMPOSITION FOR USE IN THE CUTANEOUS SYNTHESIS OF HYALURONIC ACID, IN AN IMMUNO-CUTANEOUS RESPONSE AND TO IMPROVE SKIN | JR (FR) | 2023-04-27 | — | — | WO | disclosed |
| EP-4106759-A1 | MASITINIB FOR THE TREATMENT OF A MULTIPLE SCLEROSIS PATIENT SUBPOPULATION | AB Science (FR) | 2022-12-28 | — | — | EP | disclosed |
| EP-4069230-A1 | USE OF MASITINIB FOR THE TREATMENT OF EOSINOPHILIC ASTHMA | AB Science (FR) | 2022-10-12 | — | — | EP | disclosed |
| WO-2021110737-A1 | USE OF MASITINIB FOR THE TREATMENT OF EOSINOPHILIC ASTHMA | AB SCIENCE (FR) | 2021-06-10 | — | — | WO | disclosed |
| US-10202322-B2 | Resorcinol derivatives | SUTTER BAY HOSPITALS (US) | 2019-02-12 | — | — | US | disclosed |
| US-20180170846-A1 | RESORCINOL DERIVATIVES | SUTTER WEST BAY HOSPITALS | 2018-06-21 | — | — | US | disclosed |
| US-9809521-B2 | Cannabidinoid derivatives | SUTTER WEST BAY HOSPITALS (US) | 2017-11-07 | — | — | US | disclosed |
| US-6995163-B2 | Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it | EISAI CO., LTD. (JP) | 2006-02-07 | — | — | US | disclosed |
| US-6951865-B2 | Fused heterotricyclic compounds, process for preparing the compounds and drugs containing the same | EISAI CO., LTD. (JP) | 2005-10-04 | — | — | US | disclosed |
| US-6927221-B2 | Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it | EISAI CO., LTD. (JP) | 2005-08-09 | — | — | US | disclosed |
| US-20050004147-A1 | Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it | EISAI CO., LTD. | 2005-01-06 | — | — | US | disclosed |
| US-20050004159-A1 | Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it | EISAI CO., LTD. | 2005-01-06 | — | — | US | disclosed |
| EP-1408040-A1 | Tricyclic fused heterocyclic compounds as CRFantagonists | Eisai Co., Ltd. (JP) | 2004-04-14 | — | — | EP | disclosed |
| US-20030078277-A1 | Fused heterotricyclic compounds, process for preparing the compounds and drugs containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-1238979-A1 | FUSED HETEROTRICYCLIC COMPOUNDS, PROCESS FOR PREPARING THE COMPOUNDS AND DRUGS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2002-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202322-B2 | Resorcinol derivatives | CNR1, CNR2, RCOR1 | ALDH1A1 1955/4885TDP1 3021/4885CYP3A4 336/4885 |
| US-20130209483-A1 | CANNABIDINOID DERIVATIVES | CNR2, CNR1, GPR18 | ALDH1A1 3491/4885TDP1 2676/4885CYP3A4 1389/4885 |
| US-20030078277-A1 | Fused heterotricyclic compounds, process for preparing the compounds and drugs containing the same | NR3C2, CRHR1, CRHR2 | ALDH1A1 3091/4885TDP1 4794/4885CYP3A4 1089/4885 |
| US-20050004159-A1 | Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it | CRHR2, CRHR1, NR3C2 | ALDH1A1 3794/4885TDP1 4843/4885CYP3A4 1808/4885 |
| US-20180170846-A1 | RESORCINOL DERIVATIVES | CNR1, CNR2, RCOR1 | ALDH1A1 1955/4885TDP1 3021/4885CYP3A4 336/4885 |
| US-20050004147-A1 | Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it | CRHR2, CRHR1, NR3C2 | ALDH1A1 3794/4885TDP1 4843/4885CYP3A4 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.